Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Radiotherapy (radiation treatment) is often used to treat lung cancers and lung tumors that have spread from other cancers. It can be very effective, especially in early-stage lung cancer or when there are only a few tumor sites. Even so, some patients later develop a local recurrence, meaning the cancer comes back in the same area that was previously treated with radiation.
When this happens, treatment options are limited. Surgery can sometimes remove the recurrent tumor, but many patients are not able to have surgery because of their general health or because the tumor is difficult to remove. For these patients, a second course of radiotherapy (called re-irradiation) may be the only possible treatment. One type of radiotherapy, called stereotactic body radiotherapy (SBRT), delivers very high doses of radiation very precisely. SBRT has been used successfully as a second treatment after standard radiotherapy in some patients. However, there is very little information about using SBRT again in patients who already received SBRT the first time.
Because only small studies have been done and the patients were very different from each other, doctors still do not know enough about how safe and effective a second SBRT treatment is. In particular, it is still unclear whether giving another high-dose radiation treatment is possible without causing serious side effects. More research is needed to better understand this option and help guide treatment decisions for patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| re-irradiation SBRT | Patients treated with re-irradiation SBRT on non small cell lung carcinoma |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | evaluation of treatment safety through toxicities according to the CACTE scale | from treatment to 1 years follow up |
| Measure | Description | Time Frame |
|---|---|---|
| Number of partecipant with local control | defined as the absence of progression within the field of SABR, assessed by contrast-enhanced CT scan | from enrollment to 1 years follow up |
| Time to new systemic treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients treated with Pulmonary stereotactic radiotherapy
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Davide Franceschini, MD, radiation oncologist | Contact | +39 0282247428 | davide.franceschini@cancercenter.humanitas.it | |
| Laura Bonavita, master degree | Contact | +39 0282247026 | laura.bonavita@humanitas.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AST Papa Giovanni XXIII | Recruiting | Bergamo | Bergamo | 24127 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
time from the first day of SBRT to change or starting of new systemic therapies
| from enrollment to 1 years follow up |
| Progression free survival | time from the first day of SABR until the date of detection of progressive disease (in-field or out-field) or death, whichever occurred first. | from enrollment to 1 years follow up |
| Overall survival | time from the first day of SABR to death. Patients lost to follow-up have their OS censored at the last date they were known to be alive | from enrollment to 1 years follow up |
| Dosimetric parameters related to treatment toxicity | analysis between correlation between treatment dosage and occurrence of toxicity | from enrollment to 1 years follow up |
| Radiotherapy Department, Ospedale Bellaria Carlo Alberto Pizzardi | Not yet recruiting | Bologna | Bologna | 40124 | Italy |
|
| REM Radioterapia | Not yet recruiting | Catania | Catania | 95125 | Italy |
|
| Radiation oncology unit, Ospedale San Raffaele | Not yet recruiting | Milan | Milano | 20132 | Italy |
|
| Radiotherapy Department, Istituto Europeo di Oncologia | Not yet recruiting | Milan | Milano | 20141 | Italy |
|
| IRCCS Humanitas Research Hospital | Recruiting | Rozzano | Milano | 20089 | Italy |
|
| Radiotherapy Department, IRCCS Istituto Nazionale Fondazione G. Pascale | Not yet recruiting | Naples | Napoli | 80131 | Italy |
|
| Centro Fondazione Policlinico Universitario "A. Gemelli", Radioterapia Oncologica | Not yet recruiting | Roma | Roma | 00136 | Italy |
|
| Radioterapia Oncologica - Ospedale dell'Angelo | Not yet recruiting | Venezia | Venezia | 30174 | Italy |
|
| Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center | Not yet recruiting | Negrar | Verona | 37024 | Italy |
|
| AOUI Verona, DAI Chirurgia e Oncologia - Radioterapia Oncologica | Not yet recruiting | Verona | Verona | 37126 | Italy |
|
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |